Human reproduction

Cicero Diagnostics Hits Record Growth For First Quarter 2021

Retrieved on:

Martedì, Maggio 4, 2021

Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Fertility medicine, Medical specialties, Human reproduction, Reproduction, Obstetrics, Infertility, Andrology, Endocrinology, Unexplained infertility, Reproductive endocrinology and infertility, Endometriosis, In vitro fertilisation

b'Cicero Diagnostics Inc., a women\xe2\x80\x99s healthcare diagnostic company offering the ReceptivaDx\xe2\x84\xa2 test for unexplained infertility, today announced it has reached several record milestones ending the quarter March 31.

Key Points:

b'Cicero Diagnostics Inc., a women\xe2\x80\x99s healthcare diagnostic company offering the ReceptivaDx\xe2\x84\xa2 test for unexplained infertility, today announced it has reached several record milestones ending the quarter March 31.
As of March 31, 2021, over 700 Reproductive Endocrinologists in the U.S. now access ReceptivaDx\xe2\x84\xa2, representing 80% of all fertility centers in the country.
Cicero Diagnostics is the exclusive licensed provider of BCL6 and SIRT1 for the detection of endometriosis.
Working with IVF centers across the U.S. and in 15 other countries, Cicero Diagnostics continues to expand their offering globally and is investing in continuing research in the field.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210504005393/en/\n'

Fertility in Crisis: Alife Health Aims to Improve Health Equity and Outcomes Using AI

Retrieved on:

Lunedì, Maggio 3, 2021

As fertility continues to be in crisis, new artificial intelligence (AI) supported technology looks to promote health equity and better outcomes.

Key Points:

As fertility continues to be in crisis, new artificial intelligence (AI) supported technology looks to promote health equity and better outcomes.
Alife Health, a technology company founded in 2020, is building AI tools designed to improve fertility care, starting with in vitro fertilization (IVF).
There is a tremendous opportunity for technology to transform the IVF experience and ultimately contribute to advancing human health and health equity.
Alife Health is leading this effort with its unique, technology-forward, human-centered approach,\xe2\x80\x9d said Deena Shakir, partner at Lux Capital.

Preeclampsia: Beyond Pregnancy

Retrieved on:

Lunedì, Maggio 3, 2021

Women's health, Maternal health, Human pregnancy, Human reproduction, Hypertensive disease of pregnancy, Pre-eclampsia, Maternal death, Preterm birth, Pregnancy, Intrauterine hypoxia, Complications of pregnancy

b'MELBOURNE, Fla., May 3, 2021 /PRNewswire/ --Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of premature birth and a major contributor to adverse maternal outcomes and maternal death.

Key Points:

b'MELBOURNE, Fla., May 3, 2021 /PRNewswire/ --Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of premature birth and a major contributor to adverse maternal outcomes and maternal death.
In 2013, they created The Preeclampsia Registry which now has 7,000 participants and has fueled dozens of research studies.
After a pregnancy complicated by preeclampsia, women have an increased risk of cardiovascular disease (CVD) and related mortality.
We envision a world where preeclampsia and related hypertensive disorders of pregnancy no longer threaten the lives of mothers and babies.

SCYNEXIS Presents Data at 2021 ACOG Demonstrating the Positive Outcome and Sustained Response of Investigational Oral Ibrexafungerp (Brexafemme™) in Difficult-to-Treat Patients with Vaginal Yeast Infections

Retrieved on:

Venerdì, Aprile 30, 2021

Women's health, Human reproduction, Anatomy, Gynaecology, Human female reproductive system, Bacterial vaginosis, Vaginal discharge, Vagina, VVC, Women\'s health

b'The VANISH-306 study evaluated the safety and efficacy of oral ibrexafungerp as a treatment for patients with VVC (mITT 272 subjects).

Key Points:

b'The VANISH-306 study evaluated the safety and efficacy of oral ibrexafungerp as a treatment for patients with VVC (mITT 272 subjects).
Severe VVC patients (VSS>7), categorized as complicated patients, accounted for 91.9%% of the patients in the in the study.
Typical VVC symptoms include pruritus, vaginal soreness, irritation, excoriation of vaginal mucosa and abnormal vaginal discharge.
The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization.

CenteringPregnancy Recognized by Michigan Council for Maternal and Child Health as Promising Prenatal Care Model to Improve Outcomes and Promote Health Equity in State

Retrieved on:

Giovedì, Aprile 29, 2021

Midwifery, Fertility, Reproduction, Articles, Human reproduction, Obstetrics, Childbirth, XC2, Prenatal care, Pregnancy, Prenatal development, Preterm birth

b'LANSING, Michigan, April 29, 2021 (GLOBE NEWSWIRE) -- Centering Healthcare Institute ( CHI ) today shared\xc2\xa0that the CenteringPregnancy\xc2\xae model of group prenatal care has been recognized by the Michigan Council for Maternal Child Health ( MCMCH ) in its recently released knowledge brief titled \xe2\x80\x98 Reimagining Prenatal Care\xe2\x80\x99.

Key Points:

b'LANSING, Michigan, April 29, 2021 (GLOBE NEWSWIRE) -- Centering Healthcare Institute ( CHI ) today shared\xc2\xa0that the CenteringPregnancy\xc2\xae model of group prenatal care has been recognized by the Michigan Council for Maternal Child Health ( MCMCH ) in its recently released knowledge brief titled \xe2\x80\x98 Reimagining Prenatal Care\xe2\x80\x99.
Visits meet nationally recognized clinical standards and are facilitated by a credentialed healthcare provider.
Preterm birth rate within Black patients in CenteringPregnancy groups is at 9.7% as compared to 14.6% within Michigan Medicaid\xe2\x80\x99s African American population.
CenteringPregnancy\xc2\xae and CenteringParenting\xc2\xae provide the highest quality of care to families from pregnancy through age two of the child.

Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing

Retrieved on:

Giovedì, Aprile 29, 2021

Reproduction, Branches of biology, Fertility medicine, Human reproduction, Cryobiology, Fertility, Human pregnancy, Obstetrics, In vitro fertilisation, Miscarriage, Embryo, Preimplantation genetic diagnosis

PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.

Key Points:

PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.
"\nPresagen\'s new AI product, Life Whisperer Genetics, requires only camera images of embryos to assess their genetic integrity.
Here in the USA where PGT-A testing is common, Life Whisperer Genetics would provide the opportunity to pre-screen and only test the healthiest and most viable embryos, reducing costs for our patients.
"\nPresagen plans to build additional healthcare products, both in IVF and beyond, initially focusing on women\'s health.\n'

Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing

Retrieved on:

Giovedì, Aprile 29, 2021

PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.

Key Points:

PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.
"\nPresagen\'s new AI product, Life Whisperer Genetics, requires only camera images of embryos to assess their genetic integrity.
Here in the USA where PGT-A testing is common, Life Whisperer Genetics would provide the opportunity to pre-screen and only test the healthiest and most viable embryos, reducing costs for our patients.
"\nPresagen plans to build additional healthcare products, both in IVF and beyond, initially focusing on women\'s health.\n'

CCRM Fertility Welcomes Dr. Wael Salem to its San Francisco Bay Area Location

Retrieved on:

Giovedì, Aprile 29, 2021

Fertility medicine, Articles, Reproduction, Human reproduction, In vitro fertilisation, Fertility preservation, Assisted reproductive technology, Fertility, Egg donation

b'SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- CCRM Fertility , a global pioneer in fertility treatment, research and science, welcomes Dr. Wael Salem to its San Francisco Bay Area location.

Key Points:

b'SAN FRANCISCO, April 28, 2021 /PRNewswire/ -- CCRM Fertility , a global pioneer in fertility treatment, research and science, welcomes Dr. Wael Salem to its San Francisco Bay Area location.
Dr. Salem joined CCRM Minneapolis in 2018 and relocated to the Bay Area in 2021.
CCRM Fertility specializes in the most advanced fertility treatments, with deep expertise in in vitro fertilization (IVF), fertility assessment, fertility preservation, genetic testing, third party reproduction and egg donation.
CCRM Fertility operates 11 fertility centers (including 25 offices) throughout North America, serving prospective parents in major metropolitan areas, including Atlanta, Boston, Dallas, Denver, Houston, New York, Northern Virginia, Minneapolis, Orange County, San Francisco Bay Area, and Toronto.

Global Condom Market Outlook and Forecasts 2021-2026: Latex Condoms are Expected to Reach a Revenue of Approx. $10 Billion

Retrieved on:

Mercoledì, Aprile 28, 2021

Barrier contraception, Female condom, Vagina, HIV/AIDS, Medical specialties, Condom, Human reproduction, Health

b'DUBLIN, April 28, 2021 /PRNewswire/ -- The "Condom Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nLatex condoms are expected to reach a revenue of approx.

Key Points:

b'DUBLIN, April 28, 2021 /PRNewswire/ -- The "Condom Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nLatex condoms are expected to reach a revenue of approx.
Female condoms are gaining popularity, and the market is expected to witness a significant CAGR of over 19%.\nLatex condoms are expected to reach a revenue of approx.
Many global players are expected to expand their presence worldwide during the forecast period, especially in the fast-developing countries in APAC and Latin America, to gain market share.
In addition, improving global economic conditions would fuel the growth of the market, making it an attractive time for the launch of new products.\n'

Condom Market to Grow by USD 3.70 Billion, Accelerating at a CAGR of Over 8% during 2021-2025|Technavio

Retrieved on:

Mercoledì, Aprile 28, 2021

Sexual health, HIV/AIDS, Vagina, Medical specialties, Barrier contraception, Female condom, Condom, Market analysis, Human reproduction, Articles

b'The condom market is poised to grow by USD3.70 billionduring 2021-2025, progressing at a CAGR ofover 8% during the forecast period.\nHere is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.\nThe report on the condom market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.\nThe report offers an up-to-date analysis regarding the current global market scenario and the overall market environment.The condom market analysis includes distribution channel, material, and geography landscape.

Key Points:

b'The condom market is poised to grow by USD3.70 billionduring 2021-2025, progressing at a CAGR ofover 8% during the forecast period.\nHere is an Exclusive report talking about Market scenarios, Estimates, the impact of lockdown, and Customer Behaviour.\nThe report on the condom market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.\nThe report offers an up-to-date analysis regarding the current global market scenario and the overall market environment.The condom market analysis includes distribution channel, material, and geography landscape.
This study identifies the increasing prevalence of sexually transmitted diseases as one of the prime reasons driving the condom market growth during the next few years.\nThis report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.\nThe condom market covers the following areas:\n'